Hoth Therapeutics secured regulatory approval in Spain for its Phase 2a CLEER Trial of HT-001, a topical treatment aimed at reducing skin toxicities caused by EGFR inhibitor cancer therapies. Interim results show over 65% of patients experienced significant relief from rash, pain, and itching, with no need to reduce or stop their cancer treatment. The trial's success supports Hoth's plan to expand the study across Europe, potentially improving quality of life and treatment adherence for cancer patients. This marks a key step in developing supportive care options in oncology.
Diana Burgon of Berkshire Hathaway HomeServices Bayside Realty was named to the 2025 Honor Society, recognizing the top 17% of sales professionals in the network. This award highlights her outstanding sales performance and dedication to clients. Sinc...
The Swedish Defence Materiel Administration has signed a 10-year Services Support Agreement with Bombardier to support two newly delivered Global 6500 aircraft as part of its fleet modernization. This deal includes Bombardier's Smart Services Defense...
Enpro Inc. (NPO) receives a buy rating due to its durable Sealing segment, which has maintained over 30% EBITDA margins for nine quarters, and its fast-growing semiconductor-focused AST segment, which posted a 23.3% margin in Q1 2026. The Sealing seg...
CAMSO Construction and CEAT Specialty have appointed Jason Canning as Vice President and Head of International Sales to lead their global sales strategy and drive international growth. With over 25 years of experience in specialty tyres and industria...
Anthropic held acquisition talks with robotics startup Physical Intelligence, stirring rumors despite denials. Physical Intelligence, valued at $11 billion and backed by investors including OpenAI, is known for its widely used robot brain model. The ...
